Amai Proteins sweelin approved in Israel
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 31, 2026
The approval expands Amai Proteins' market access, potentially accelerating adoption of its sweet protein in the food and beverage industry and strengthening its commercial position. This regulatory milestone may positively influence investor sentiment toward the company and the broader alternative sweetener sector, though Amai Proteins is privately held.
Amai Proteins, an Israeli food-tech company, announced that the Israeli Ministry of Health has approved its precision-fermented sweet protein sweelin as a novel food ingredient for use in over 25 food and beverage categories. This approval marks the third regulatory clearance for sweelin in less than six months, following approvals from the U.S. United States — Food and Drug Administration (GRAS) and the Singapore — Singapore Food Agency. The company highlights sweelin's ability to reduce sugar by up to 70% while being 3,000 times sweeter than sugar, with published clinical evidence showing no effect on blood glucose, insulin, or GLP-1 levels. CEO Amir Guttman expressed pride in being the first sweet protein approved in Israel and emphasized the commercial milestone. The approval enables Israeli manufacturers to commercialize products containing sweelin, supporting the growing demand for clean-label and GLP-1 friendly products.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard